目次

1. Monitoring of Anticoagulant Therapy in Patients Being Treated withWarfarin; 2. Monitoring of Anticoagulant Therapy in Patients Being Treatedwith Unfractionated Heparin; 3. Monitoring of Anticoagulant Therapy inPatients Being Treated with Low Molecular Weight Heparin; 4. Monitoring ofAnticoagulant Therapy in Patients Being Treated with Fondaparinux; 5.Monitoring of Anticoagulant Therapy in Patients Being Treated with Lepirudinor Argatroban; 6. Evaluation for HIT; 7. Evaluation of Prolongations of thePT and the PTT and Assessment for Deficiencies of Coagulation Factors; 8.Evaluation for Disseminated Intravascular Coagulation; 9. Evaluation for aCongenital Hypercoagulable State; 10. Evaluation for AntiphospholipidAntibodies; 11. Evaluation for von Willebrand Disease; 12. Evaluation for aCoagulation Factor VIII Inhibitor; 13. Evaluation for Thrombocytopenia ThatIs Not Associated with Heparin Exposure; 14. Evaluation for PlateletDysfunction in the Presence or Absence of Antiplatelet Agents